Comments
The pharma major Dr Reddy's Laboratories on Friday announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, in the US market.
The Precedex in 0.9% sodium chloride injection brand had sales of approximately $210 million for the most recent twelve months ending in June 2020, according to IQVIA Health data.
Snapping two-day losing streak, the company's shares gained as much as 2.2 per cent to ₹5,139 in noon trade.
Related Stories
Dr Reddy’s trials for Russia’s Sputnik-V vaccine could start in next few weeks
Trials of the vaccine candidate will enrol 1,000-2,000 participants
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.